Oxford Asset Management’s Innate Pharma IPHA Stock Holding History

Oxford Asset Management’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$196K	Sell	29,397 -14,829	-34%	-$100K	0.03%	118
2019 Q4	$284K	Buy	+44,226	New	+$272K	0.01%	1454

Other funds holding IPHA

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Oxford Asset Management's IPHA Position: Q1 2020 in Review

Oxford Asset Management reduced its Innate Pharma (IPHA) stake by 34% in Q1 2020, selling an estimated $100K and leaving 29,397 shares worth $196K. The position accounts for 0.03% of the portfolio, ranked #118.

Oxford Asset Management first reported a position in IPHA in Q4 2019 and has held it in 2 quarters since. The position peaked at $284K in Q4 2019. 10 funds tracked by Wall St. Rank hold IPHA as of Q1 2020.

Oxford Asset Management held 29,397 shares of Innate Pharma worth $196K as of Q1 2020.
Oxford Asset Management sold 14,829 Innate Pharma shares in Q1 2020, an estimated $100K.
Innate Pharma made up 0.03% of Oxford Asset Management's portfolio in Q1 2020, its #118 holding.
Oxford Asset Management first reported a position in Innate Pharma in Q4 2019 and has held it in 2 quarters since.
Oxford Asset Management's Innate Pharma position peaked at $284K in Q4 2019.
10 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.